Chushu Li

PD-1 disrupted CAR-T cells in the treatment of solid tumors: Promises and challenges

Proteasomal and lysosomal degradation for specific and durable suppression of immunotherapeutic targets

PROTAC targeted protein degraders: the past is prologue

PD‐1/PD‐L1 immune checkpoint: Potential target for cancer therapy

Ionizable Lipid Nanoparticles with Integrated Immune Checkpoint Inhibition for mRNA CAR T Cell Engineering

HIP1R targets PD-L1 to lysosomal degradation to alter T cell–mediated cytotoxicity

Cancer Cell-Intrinsic PD-1 and Implications in Combinatorial Immunotherapy

Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune Evasion

Rise of PD‐L1 expression during metastasis of colorectal cancer: Implications for immunotherapy